Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) Debt to Equity (2021 - 2025)

Indivior Pharmaceuticals has reported Debt to Equity over the past 5 years, most recently at -$3.26 for Q4 2025.

  • Quarterly results put Debt to Equity at -$3.26 for Q4 2025, down 229.42% from a year ago — trailing twelve months through Dec 2025 was -$3.26 (down 229.42% YoY), and the annual figure for FY2025 was -$3.26, down 229.42%.
  • Debt to Equity for Q4 2025 was -$3.26 at Indivior Pharmaceuticals, down from -$1.56 in the prior quarter.
  • Over the last five years, Debt to Equity for INDV hit a ceiling of $2.0 in Q4 2021 and a floor of -$16.0 in Q4 2022.
  • Median Debt to Equity over the past 5 years was -$1.29 (2023), compared with a mean of -$2.94.
  • Biggest five-year swings in Debt to Equity: tumbled 900.0% in 2022 and later surged 91.85% in 2023.
  • Indivior Pharmaceuticals' Debt to Equity stood at $2.0 in 2021, then tumbled by 900.0% to -$16.0 in 2022, then surged by 91.85% to -$1.3 in 2023, then grew by 24.24% to -$0.99 in 2024, then tumbled by 229.42% to -$3.26 in 2025.
  • The last three reported values for Debt to Equity were -$3.26 (Q4 2025), -$1.56 (Q3 2025), and -$1.27 (Q2 2025) per Business Quant data.